{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:43:59Z","timestamp":1790837039861,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000200","name":"USAID","doi-asserted-by":"crossref","award":["AID-486-LA-15-00002"],"award-info":[{"award-number":["AID-486-LA-15-00002"]}],"id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Integrated drug efficacy surveillance (iDES) was formally introduced nationally across Thailand in fiscal year 2018 (FY2018), building on a history of drug efficacy monitoring and interventions. According to the National Malaria Elimination Strategy for Thailand 2017\u20132026, diagnosis is microscopically confirmed, treatment is prescribed, and patients are followed up four times to ensure cure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Routine patient data were extracted from the malaria information system for FY2018\u2013FY2020. Treatment failure of first-line therapy was defined as confirmed parasite reappearance within 42\u00a0days for <jats:italic>Plasmodium falciparum<\/jats:italic> and 28\u00a0days for <jats:italic>Plasmodium vivax<\/jats:italic>. The primary outcome was the crude drug efficacy rate, estimated using Kaplan\u2013Meier methods, at day 42 for <jats:italic>P. falciparum<\/jats:italic> treated with dihydroartemisinin\u2013piperaquine plus primaquine, and day 28 for <jats:italic>P. vivax<\/jats:italic> treated with chloroquine plus primaquine; day 60 and day 90 efficacy were secondary outcomes for <jats:italic>P. vivax<\/jats:italic>.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The proportion of patients with outcomes recorded at day 42 for <jats:italic>P. falciparum<\/jats:italic> malaria and at day 28 for <jats:italic>P. vivax<\/jats:italic> malaria has been increasing, with FY2020 follow-up rates of 61.5% and 57.2%, respectively. For <jats:italic>P. falciparum<\/jats:italic> malaria, day 42 efficacy in FY2018 was 92.4% (n\u2009=\u2009249), in FY2019 93.3% (n\u2009=\u2009379), and in FY2020 98.0% (n\u2009=\u2009167). <jats:italic>Plasmodium falciparum<\/jats:italic> recurrences occurred disproportionally in Sisaket Province, with day 42 efficacy rates of 75.9% in FY2018 (n\u2009=\u200959) and 49.4% in FY2019 (n\u2009=\u200949), leading to an update in first-line therapy to pyronaridine\u2013artesunate at the provincial level, rolled out in FY2020. For <jats:italic>P. vivax<\/jats:italic> malaria, day 28 efficacy (chloroquine efficacy) was 98.5% in FY2018 (n\u2009=\u20092048), 99.1% in FY2019 (n\u2009=\u20092206), and 99.9% in FY2020 (n\u2009=\u20092448), and day 90 efficacy (primaquine efficacy) was 94.8%, 96.3%, and 97.1%, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In Thailand, iDES provided operationally relevant data on drug efficacy, enabling the rapid amendment of treatment guidelines to improve patient outcomes and reduce the potential for the spread of drug-resistant parasites. A strong case-based surveillance system, integration with other health system processes, supporting biomarker collection and molecular analyses, and cross-border collaboration may maximize the potential of iDES in countries moving towards elimination.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-021-03791-2","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T14:47:49Z","timestamp":1623250069000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Progress and challenges of integrated drug efficacy surveillance for uncomplicated malaria in Thailand"],"prefix":"10.1186","volume":"20","author":[{"given":"Prayuth","family":"Sudathip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aungkana","family":"Saejeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nardlada","family":"Khantikul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thannikar","family":"Thongrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suravadee","family":"Kitchakarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rungniran","family":"Sugaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheewanan","family":"Lertpiriyasuwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darin","family":"Areechokchai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyer","family":"Gopinath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sintasath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Ringwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathapana","family":"Naowarat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niparueradee","family":"Pinyajeerapat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Dorina","family":"Bustos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5723-4738","authenticated-orcid":false,"given":"Jui A.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,9]]},"reference":[{"key":"3791_CR1","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/S1473-3099(20)30228-0","volume":"20","author":"M Imwong","year":"2020","unstructured":"Imwong M, Dhorda M, Myo Tun K, Thu AM, Phyo AP, Proux S, et al. Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study. Lancet Infect Dis. 2020;20:1470\u201380.","journal-title":"Lancet Infect Dis"},{"key":"3791_CR2","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/1475-2875-11-247","volume":"11","author":"A Khamsiriwatchara","year":"2012","unstructured":"Khamsiriwatchara A, Sudathip P, Sawang S, Vijakadge S, Potithavoranan T, Sangvichean A, et al. Artemisinin resistance containment project in Thailand. (I): implementation of electronic-based malaria information system for early case detection and individual case management in provinces along the Thai-Cambodian border. Malar J. 2012;11:247.","journal-title":"Malar J"},{"key":"3791_CR3","unstructured":"WHO Regional Office for the Western Pacific. Strategy for malaria elimination in the Greater Mekong Subregion: 2015\u20132030. World Health Organization Regional Office for the Western Pacific; 2015. https:\/\/apps.who.int\/iris\/handle\/10665\/208203. Accessed 18 Feb 2021."},{"key":"3791_CR4","unstructured":"Bureau of Vector Borne Diseases, Department of Disease Control, Ministry of Public Health Thailand. Guide to malaria elimination for Thailand's local administrative organizations and the health network. Nonthaburi: Thailand; 2019. http:\/\/malaria.ddc.moph.go.th\/downloadfiles\/Guide%20to%20Malaria%20Elimination%20for%20Thailand%20LAO_EN.pdf. Accessed 9 Oct 2020."},{"key":"3791_CR5","unstructured":"Bureau of Vector Borne Diseases, Department of Disease Control, Ministry of Public Health Thailand. National malaria elimination strategy for Thailand 2017\u20132026. Nonthaburi: Thailand; 2016."},{"key":"3791_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3390\/tropicalmed4040143","volume":"4","author":"P Sudathip","year":"2019","unstructured":"Sudathip P, Kitchakarn S, Thimasarn K, Gopinath D, Naing T, Sajjad O, et al. The evolution of the malaria clinic: the cornerstone of malaria elimination in Thailand. Trop Med Infect Dis. 2019;4:143.","journal-title":"Trop Med Infect Dis"},{"key":"3791_CR7","unstructured":"USAID. US President's malaria initiative: Thailand, Lao PDR and regional abbreviated malaria operation plan FY 2019. United States Agency for International Development; 2019. https:\/\/www.pmi.gov\/docs\/default-source\/default-document-library\/malaria-operational-plans\/fy19\/fy-2019-thailand-abbreviated-malaria-operational-plan.pdf?sfvrsn=5. Accessed 9 Oct 2020."},{"key":"3791_CR8","unstructured":"WHO. World malaria report. Geneva, World Health Organization; 2020. https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2020. Accessed 13 Dec 2020."},{"key":"3791_CR9","unstructured":"Division of Vector Borne Diseases, Department of Disease Control, Ministry of Public Health Thailand. Malaria Online: the digital surveillance system for Thailand malaria elimination. Nonthaburi: Thailand; 2020. https:\/\/publicadministration.un.org\/unpsa\/Portals\/0\/UNPSA_Submitted_Docs\/2019\/3fe4c1ba-e00b-4250-8816-f513c3b209c6\/2020%20UNPSA_Malaria%20online_full%20report_27112019_111848_f62725d9-bd75-4846-a44c-8524838f4e87.pdf?ver=1441-03-30-111848-927. Accessed 10 Oct 2020."},{"key":"3791_CR10","unstructured":"USAID. US President\u2019s malaria initiative: Thailand, Lao PDR, and regional malaria operation plan FY 2018. United States Agency for International Development. 2018. https:\/\/www.pmi.gov\/docs\/default-source\/default-document-library\/malaria-operational-plans\/fy-2018\/fy-2018-thailand-regional-malaria-operational-plan.pdf?sfvrsn=8. Accessed 9 Oct 2020."},{"key":"3791_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1475-2875-8-31","volume":"8","author":"RJ Maude","year":"2009","unstructured":"Maude RJ, Pontavornpinyo W, Saralamba S, Aguas R, Yeung S, Dondorp AM, et al. The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia. Malar J. 2009;8:31.","journal-title":"Malar J"},{"key":"3791_CR12","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/1475-2875-11-300","volume":"11","author":"W Satimai","year":"2012","unstructured":"Satimai W, Sudathip P, Vijaykadga S, Khamsiriwatchara A, Sawang S, Potithavoranan T, et al. Artemisinin resistance containment project in Thailand. II: responses to mefloquine-artesunate combination therapy among falciparum malaria patients in provinces bordering Cambodia. Malar J. 2012;11:300.","journal-title":"Malar J"},{"key":"3791_CR13","unstructured":"WHO. Methods for surveillance of antimalarial drug efficacy. Geneva, World Health Organization; 2009. https:\/\/www.who.int\/malaria\/publications\/atoz\/9789241597531\/en\/. Accessed 13 Dec 2020."},{"key":"3791_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4269\/ajtmh.16-0160","volume":"95","author":"PL Olliaro","year":"2016","unstructured":"Olliaro PL, Barnwell JW, Barry A, Mendis K, Mueller I, Reeder JC, et al. Implications of Plasmodium vivax biology for control, elimination, and research. Am J Trop Med Hyg. 2016;95:4\u201314.","journal-title":"Am J Trop Med Hyg"},{"key":"3791_CR15","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1093\/cid\/ciy319","volume":"67","author":"CS Chu","year":"2018","unstructured":"Chu CS, Phyo AP, Lwin KM, Win HH, San T, Aung AA, et al. Comparison of the cumulative efficacy and safety of chloroquine, artesunate, and chloroquine-primaquine in Plasmodium vivax malaria. Clin Infect Dis. 2018;67:1543\u20139.","journal-title":"Clin Infect Dis"},{"key":"3791_CR16","volume-title":"Practice guidelines for the treatment of patients with malaria","author":"Ministry of Public Health Thailand","year":"2019","unstructured":"Ministry of Public Health Thailand. Practice guidelines for the treatment of patients with malaria. Nonthaburi: Ministry of Public Health Thailand; 2019."},{"key":"3791_CR17","volume-title":"Department of Disease Control, Ministry of Public Health Thailand: Standard operating procedures (SOP) for malaria case follow up in Thailand","author":"Division of Vector Borne Diseases","year":"2019","unstructured":"Division of Vector Borne Diseases. Department of Disease Control, Ministry of Public Health Thailand: Standard operating procedures (SOP) for malaria case follow up in Thailand. Nonthaburi: Division of Vector Borne Diseases; 2019."},{"key":"3791_CR18","unstructured":"WHO Regional Office for the Western Pacific. Fifth Meeting of the Greater Mekong Subregion (GMS) Therapeutic Efficacy Studies (TES) Network, Ho Chi Minh City, Viet Nam, 28\u201329 September 2017: meeting report. World Health Organization Regional Office for the Western Pacific; 2017. https:\/\/apps.who.int\/iris\/handle\/10665\/260008. Accessed 10 Oct 2020."},{"key":"3791_CR19","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/S1473-3099(19)30391-3","volume":"19","author":"RW van der Pluijm","year":"2019","unstructured":"van der Pluijm RW, Imwong M, Chau NH, Hoa NT, Thuy-Nhien NT, Thanh NV, et al. Determinants of dihydroartemisinin\u2013piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infect Dis. 2019;19:952\u201361.","journal-title":"Lancet Infect Dis"},{"key":"3791_CR20","first-page":"943","volume":"20","author":"K Stepniewska","year":"2020","unstructured":"Stepniewska K, Humphreys GS, Gon\u00e7alves BP, Craig E, Gosling R, Guerin PJ, et al. Efficacy of single-dose primaquine with artemisinin combination therapy on Plasmodium falciparum gametocytes and transmission: an individual patient meta-analysis. J Infect Dis. 2020;20:943\u201352.","journal-title":"J Infect Dis"},{"key":"3791_CR21","unstructured":"WHO\/TDR. Microscopy for the detection, identification and quantification of malaria parasites on stained thick and thin blood films in research settings. Geneva, World Health Organization Special Programme for Research and Training in Tropical Diseases; 2015. https:\/\/www.who.int\/tdr\/publications\/microscopy_detec_ident_quantif\/en\/. Accessed 10 Oct 2020."},{"key":"3791_CR22","unstructured":"USAID. US President's malaria initiative Thailand, Lao PDR and regional malaria operational plan FY 2020. United States Agency for International Development; 2020. https:\/\/www.pmi.gov\/docs\/default-source\/default-document-library\/malaria-operational-plans\/fy20\/fy-2020-thailand-malaria-operational-plan.pdf?sfvrsn=6. Accessed 10 Oct 2020."},{"key":"3791_CR23","unstructured":"WHO. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. Geneva, World Health Organization; 2008. http:\/\/www.who.int\/malaria\/publications\/atoz\/9789241596305\/en\/. Accessed 13 Dec 2020."},{"key":"3791_CR24","unstructured":"Institut Pasteur du Cambodge. PCR and sequencing for genotyping of candidate Plasmodium falciparum artemisinin resistance SNPs in the Kelch 13 gene v1.0. Institut Pasteur du Cambodge; 2013. https:\/\/www.wwarn.org\/tools-resources\/procedures\/pcr-and-sequencing-genotyping-candidate-plasmodium-falciparum-artemisinin. Accessed 20 Feb 2021."},{"key":"3791_CR25","unstructured":"WWARN. Copy number estimation of P. falciparum pfmdr1 v1.1. WorldWide Antimalarial Resistance Network; 2011. https:\/\/www.wwarn.org\/sites\/default\/files\/attachments\/procedures\/MOL05_CopyEstimationPfalciparum_pfmdr1.pdf. Accessed 9 Oct 2020."},{"key":"3791_CR26","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12936-021-03648-8","volume":"20","author":"P Sudathip","year":"2021","unstructured":"Sudathip P, Kitchakarn S, Shah J, Bisanzio D, Young F, Gopinath D, et al. A foci cohort analysis to monitor successful and persistent foci under Thailand\u2019s malaria elimination strategy. Malar J. 2021;20:118.","journal-title":"Malar J"},{"key":"3791_CR27","unstructured":"WHO. mHealth: new horizons for health through mobile technologies. Geneva: World Health Organization; 2011. https:\/\/www.who.int\/goe\/publications\/goe_mhealth_web.pdf. Accessed 27 Oct 2020."},{"key":"3791_CR28","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1093\/cid\/ciz580","volume":"70","author":"P Quang Bui","year":"2020","unstructured":"Quang Bui P, Hong Huynh Q, Thanh Tran D, Le Thanh D, Quang Nguyen T, Van Truong H, et al. Pyronaridine\u2013artesunate efficacy and safety in uncomplicated Plasmodium falciparum malaria in areas of artemisinin-resistant falciparum in Viet Nam (2017\u20132018). Clin Infect Dis. 2020;70:2187\u201395.","journal-title":"Clin Infect Dis"},{"key":"3791_CR29","first-page":"e02242","volume":"63","author":"R Leang","year":"2019","unstructured":"Leang R, Mairet-Khedim M, Chea H, Huy R, Khim N, Mey Bouth D, et al. Efficacy and safety of pyronaridine\u2013artesunate plus single-dose primaquine for treatment of uncomplicated Plasmodium falciparum malaria in eastern Cambodia. Antimicrob Agents Chemother. 2019;63:e02242-e2318.","journal-title":"Antimicrob Agents Chemother"},{"key":"3791_CR30","first-page":"e01273","volume":"63","author":"R Leang","year":"2019","unstructured":"Leang R, Khim N, Chea H, Huy R, Mairet-Khedim M, Mey Bouth D, et al. Efficacy and safety of pyronaridine\u2013artesunate plus single-dose primaquine for the treatment of malaria in western Cambodia. Antimicrob Agents Chemother. 2019;63:e01273-e1319.","journal-title":"Antimicrob Agents Chemother"},{"key":"3791_CR31","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.4269\/ajtmh.20-0185","volume":"103","author":"KT Han","year":"2020","unstructured":"Han KT, Lin K, Han ZY, Myint MK, Aye KH, Thi A, et al. Efficacy and safety of pyronaridine\u2013artesunate for the treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax malaria in Myanmar. Am J Trop Med Hyg. 2020;103:1088\u201393.","journal-title":"Am J Trop Med Hyg"},{"key":"3791_CR32","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ijpddr.2018.04.003","volume":"8","author":"K Tantiamornkul","year":"2018","unstructured":"Tantiamornkul K, Pumpaibool T, Piriyapongsa J, Culleton R, Lek-Uthai U. The prevalence of molecular markers of drug resistance in Plasmodium vivax from the border regions of Thailand in 2008 and 2014. Int J Parasitol Drugs Drug Resist. 2018;8:229\u201337.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"3791_CR33","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/jac\/dkaa092","volume":"75","author":"C Roesch","year":"2020","unstructured":"Roesch C, Mairet-Khedim M, Kim S, Lek D, Popovici J, Witkowski B. Impact of the first-line treatment shift from dihydroartemisinin\/piperaquine to artesunate\/mefloquine on Plasmodium vivax drug susceptibility in Cambodia. J Antimicrob Chemother. 2020;75:1766\u201371.","journal-title":"J Antimicrob Chemother"},{"key":"3791_CR34","doi-asserted-by":"publisher","first-page":"e181449","DOI":"10.1001\/jamanetworkopen.2018.1449","volume":"1","author":"JK Baird","year":"2018","unstructured":"Baird JK, Louisa M, Noviyanti R, Ekawati L, Elyazar I, Subekti D, et al. Association of impaired cytochrome P450 2D6 activity genotype and phenotype with therapeutic efficacy of primaquine treatment for latent Plasmodium vivax malaria. JAMA Netw Open. 2018;1:e181449.","journal-title":"JAMA Netw Open"},{"key":"3791_CR35","doi-asserted-by":"publisher","first-page":"e0188613","DOI":"10.1371\/journal.pone.0188613","volume":"12","author":"P Dharmawardena","year":"2017","unstructured":"Dharmawardena P, Rodrigo C, Mendis K, Gunasekera AWGW, Premaratne R, Ringwald P, et al. Response of imported malaria patients to antimalarial medicines in Sri Lanka following malaria elimination. PLoS ONE. 2017;12:e0188613.","journal-title":"PLoS ONE"},{"key":"3791_CR36","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.4269\/ajtmh.18-0897","volume":"100","author":"P Sudathip","year":"2019","unstructured":"Sudathip P, Kongkasuriyachai D, Stelmach R, Bisanzio D, Sine J, Sawang S, et al. The investment case for malaria elimination in Thailand: a cost-benefit analysis. Am J Trop Med Hyg. 2019;100:1445\u201353.","journal-title":"Am J Trop Med Hyg"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03791-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-021-03791-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03791-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T14:53:20Z","timestamp":1623250400000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-021-03791-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,9]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3791"],"URL":"https:\/\/doi.org\/10.1186\/s12936-021-03791-2","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,9]]},"assertion":[{"value":"18 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PS, AS, NK, TT, SK, RS, CL, and DA are employees of the Division of Vector Borne Diseases, Ministry of Public Health, Thailand. JAS and SN are employees of RTI International, Thailand. DG, PR, and MDB are staff members of the World Health Organization; the authors alone are responsible for the views expressed in this publication that do not necessarily represent the decisions, policy, or views of the World Health Organization. NP and DS are employees of the Regional Development Mission for Asia, United States Agency for International Development, Thailand. The authors have no further conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"261"}}